Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155710 · ClinicalTrials.gov registry record · Phase 1
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
A Phase 1 study, sponsored by Iovance Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04155710 is a Phase 1 study that has completed, run by Iovance Biotherapeutics. The registered enrollment target is 7 participants.
The verdict
NCT04155710, a Phase 1 study, has completed, sponsored by Iovance Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
Interventions
- DRUG IL-2
- BIOLOGICAL IOV-2001
- DRUG Low dose IL-2
- DRUG High dose IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04155710
The ClinicalTrials.gov registry entry for NCT04155710 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which IL-2 is the first listed.
NCT04155710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04155710 about?
NCT04155710 is a clinical study titled "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL". This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
What is the current status of trial NCT04155710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-02-19. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT04155710?
The interventions under investigation include: IL-2 (DRUG), IOV-2001 (BIOLOGICAL), Low dose IL-2 (DRUG), High dose IL-2 (DRUG).
Who is sponsoring clinical trial NCT04155710?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.